Loading...
•
Dec 31, 2019
Bio-Techne Q2 2020 Earnings Report
Bio-Techne's Q2 2020 financial results were released, featuring revenue growth and increased EPS.
Key Takeaways
Bio-Techne reported a solid second quarter with a 6% increase in organic revenue, reaching $184.9 million. GAAP EPS was $3.02, driven by a gain on the ChemoCentryx investment, while adjusted EPS increased by 2% to $1.08. The Diagnostics and Genomics segment showed strong organic growth of 12%.
Second quarter organic revenue increased by 6% to $184.9 million.
GAAP EPS was $3.02, including a gain from the ChemoCentryx investment; adjusted EPS was $1.08, a 2% increase.
Adjusted Operating Margin increased to 33.4% compared to 32.5% in the prior year.
Diagnostics and Genomics segment delivered organic growth of 12%.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...